Introduction
Two alemtuzumab courses significantly improved efficacy outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS) in two phase 3 trials (Comparison of Alemtuzumab and Rebif ® Efficacy in Multiple Sclerosis (CARE-MS) I and II). 1, 2 In the CARE-MS extension study, efficacy was maintained through Year 6, including improvements in preexisting disability and significant slowing of brain volume loss (BVL), [3] [4] [5] [6] with 64% (CARE-MS I) and 55% (CARE-MS II) of patients not receiving additional alemtuzumab after the initial two courses. 6 The effects of alemtuzumab over 6 years in the absence of continuous treatment may be due to its selective depletion and distinct pattern of repopulation of circulating CD52-expressing T and B lymphocytes. [7] [8] [9] Adverse events (AEs) associated with alemtuzumab treatment in clinical trials and postmarketing experience include infusion-associated reactions (IARs), increased frequency of infection and the potential for opportunistic infections, secondary autoimmunity (thyroid disorders, immune thrombocytopenia, nephropathies, autoimmune cytopenias, autoimmune hepatitis, and other less common autoimmune events), acute acalculous cholecystitis, and cardiovascular and pulmonary events possibly related to infusion. 1, 2, [4] [5] [6] [10] [11] [12] [13] Alemtuzumab is administered as two courses at 12 mg/day intravenously on five consecutive days at baseline and three consecutive days 12 months later. 11, 14 Product labeling allows for additional courses as needed in certain countries, for example, in the United States (no limit) 14 and in Australia and Europe (up to 2). 11, 15 As with other disease-modifying therapies (DMTs), [16] [17] [18] some alemtuzumab-treated patients may relapse within the first year of therapy. An important question is whether patients relapsing between the first and second alemtuzumab courses can expect to achieve control of disease activity after completion of the second course. In this post hoc analysis, 6-year clinical and magnetic resonance imaging (MRI) outcomes were assessed in CARE-MS alemtuzumab-treated patients who relapsed between Courses 1 and 2 (referred to here as "early relapsers") and in those patients without early relapse ("early non-relapsers").
Materials and methods

Patients and procedures
This post hoc analysis included patients who received alemtuzumab in the core CARE-MS I and II trials (NCT00530348; NCT00548405), subsequently entered the extension study (CAMMS03409; NCT00930553), and had up to 6 years of follow-up after initiating alemtuzumab (2 years in the core study and 4 years in the extension). 1, 2, 4, 5 Patient subgroups were defined according to relapse in Months 0-12 (between Courses 1 and 2).
The study designs for the CARE-MS core and extension studies were published previously. 1, 2, 4, 5 Briefly, CARE-MS I and II were randomized, rater-blinded, active-controlled, head-to-head trials of alemtuzumab (12 mg/day intravenously on five consecutive days at baseline and three consecutive days 12 months later) compared with SC IFNB-1a (44 μg three times per week) in patients with active RRMS (⩾2 relapses in the previous 2 years and ⩾1 relapse in the prior year) who were treatment naive (CARE-MS I) 1 or had inadequate response to prior therapy with IFNB or glatiramer acetate (CARE-MS II). 2 Patients completing the core studies could enroll in the extension and receive additional alemtuzumab (12 mg/day intravenously on three consecutive days), as needed for disease activity, ⩾12 months after the previous infusion. 4, 5 Criteria for additional courses were ⩾1 protocol-defined relapse, or ⩾2 new/enlarging T2 hyperintense and/or new gadolinium (Gd)-enhancing T1 brain or spinal cord lesions on MRI; investigators had discretion whether to administer additional courses to qualifying patients. Use of other DMTs was permitted during the extension at investigator's discretion (no criteria). Patients who received SC IFNB-1a in the core CARE-MS studies and who switched to alemtuzumab were not included in this analysis.
All procedures were approved by local institutional ethics review boards of participating sites. Patients provided written informed consent. 4, 5 Outcome measures Patient characteristics were assessed at baseline. Details regarding relapse assessment, Expanded Disability Status Scale (EDSS) scores, and MRI scans were described previously; 4-6 details on the MRI methodology are shown in the Supplementary Material. Post hoc subgroup analyses over 6 years included the following: annualized relapse rate (ARR); 6-month confirmed disability worsening (CDW; ⩾1.0-point EDSS score increase from core study baseline (⩾1.5 if baseline EDSS score = 0)); 6-month confirmed disability improvement (CDI; ⩾1.0-point decrease from the core study baseline EDSS score, in patients with baseline EDSS scores ⩾ 2.0); absence of MRI disease activity (new Gd-enhancing and new/enlarging T2 hyperintense lesions); and median percentage BVL, derived by relative change in brain parenchymal fraction (BPF; calculated from proton density/ T2-weighted dual-echo images using brain segmentation software developed at the Cleveland Clinic (Cleveland, OH)). Analyses also included proportions of patients with MRI lesions (Gd-enhancing, new/ enlarging T2 hyperintense, and new non-enhancing T1 hypointense lesions) and no evidence of disease activity (NEDA, absence of both clinical disease activity (relapses and 6-month CDW) and MRI disease activity).
Statistical analysis
Analyses were based on available data (without imputation) on all patients administered with alemtuzumab 12 mg up to 6 years of follow-up from the first dose in CARE-MS I or II. Comparison of baseline characteristics between early relapsers and early non-relapsers was done using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables. The p values obtained were nominal and not adjusted for multiple comparisons.
ARR was estimated using negative binomial regression with robust variance estimation. Proportions of patients with 6-month CDW or 6-month CDI were estimated with the Kaplan-Meier method. Yearly percentage BPF changes and proportions of patients free of Gd-enhancing, new T1 hypointense, or new/enlarging T2 hyperintense lesions were reported. NEDA and freedom from MRI disease activity were evaluated annually.
Results
15%-24% of patients relapsed between Courses 1 and 2 of alemtuzumab
Of 376 patients who received alemtuzumab 12 mg in CARE-MS I, 56 (15%) relapsed within 12 months after treatment initiation; a higher percentage of early relapsers was observed among CARE-MS II patients (105/435 (24%) Figure 1 
Early relapsers had increased baseline disease activity
Before alemtuzumab treatment, early relapsers from each CARE-MS study had a significantly higher mean EDSS score than early non-relapsers and significantly more relapses in the prior 1-2 years ( Table 1 ). The CARE-MS I early relapse group also had a significantly higher percentage of female patients. Despite relapse in the first year, 82% (CARE-MS I) and 79% (CARE-MS II) of patients were free of Gd-enhancing lesions, 54% and 56% were free of new/enlarging T2 hyperintense lesions, 71% and 80% were free of new non-enhancing T1 hypointense lesions, and 54% and 55% were free of MRI disease activity during that year (Figure 3 Early relapsers showed moderately elevated relapse risk and disability worsening In Year 6, ARR was comparable between early relapsers and early non-relapsers in CARE-MS II but was slightly elevated in CARE-MS I early relapsers non-relapsers but was slightly lower in the CARE-MS I early relapsing cohort (eTable 2).
Efficacy outcomes in early relapsers after
Discussion
Limited practical guidance exists regarding management of patients with early on-treatment relapse following initiation of DMT. 19 Relapse soon after treatment initiation may indicate suboptimal response, and a switch to an alternative DMT may be considered. 19 The unique dosing regimen of alemtuzumab for treatment of relapsing forms of MS, consisting of two courses a year apart and additional courses as needed, includes a 12-month period in which patients have received a partial alemtuzumab dose, until they receive the second course. 11, 14 For some patients, the full immune modulatory effect may not be realized until after completing the two-course regimen. The results of this post hoc analysis indicate that patients who relapse within 12 months after the first alemtuzumab course may benefit from completing the treatment as approved, that is, by receiving the second course. After completion of the two-course regimen, clinical and MRI lesion outcomes were improved, despite clinical relapse after the first course. However, early relapsers responded to Course 1 of alemtuzumab, despite their relapse activity, as the percentage of patients free of Gd-enhancing lesions improved from baseline to Year 1. The retention rates (80% in CARE-MS I; 72% in CARE-MS II) among early relapsers lend strength to the dataset, although they were slightly lower than those of early non-relapsers at Year 6 (88% and 81%, respectively).
In general, relapses are not uncommon in the first year of treatment with DMTs. For DMTs that are administered continuously, the percentages of patients relapsing within 12 months of treatment initiation were 32%-43% with SC IFNB-1a in the CARE-MS core studies, 17% with fingolimod in the TRANSFORMS study, 16 23% with natalizumab in the AFFIRM study, 17 and 28% with intramuscular IFNB-1a and natalizumab combination therapy in the SENTINEL study. 18 The proportions of patients with active RRMS relapsing within 12 months after the first alemtuzumab course in this study were 15% (CARE-MS I) and 24% (CARE-MS II). Despite patient differences across studies of various DMTs, each therapy had a population with disease activity occurring shortly after initiation.
Disease activity soon after initiating a DMT does not necessarily represent treatment failure. 20 Studies of other DMTs have shown that pretreatment relapse activity is predictive of on-treatment disease activity, including relapses, 21-23 suggesting a higher underlying propensity for disease activity in some patients. This is supported in our study by the finding that, compared with patients without relapse between Courses 1 and 2, early relapsers had a higher mean number of relapses in the 1−2 years before study entry and a higher baseline mean EDSS score. Notably, a greater proportion of CARE-MS II patients relapsed within 12 months after the first alemtuzumab course compared with patients from CARE-MS I. Although pretreatment relapse activity was numerically similar among early relapsers in both studies, CARE-MS I enrollees had relapsed while treatment naive, whereas CARE-MS II patients had relapsed, despite prior therapy. The higher risk for early relapse in CARE-MS II patients is thus consistent with a greater baseline propensity for treatment-resistant MS disease activity in that study population. CARE-MS II enrollees also had a longer disease duration than CARE-MS I patients, but relapse rates tend to decrease over time, 24 suggesting that disease duration is unlikely to account for the observed difference in on-study relapses.
Early relapsers showed improvements in efficacy outcomes after Course 2 which were maintained through 6 years. These patients had similar MRI outcomes as early non-relapsers, but showed an increased risk for relapse and disability worsening, and decreased disability improvement. Moreover, fewer early relapsers achieved NEDA over 6 years compared with early non-relapsers. As early relapsers may have intrinsically more severe MS, they may need closer monitoring for clinical disease activity compared with patients who do not relapse between Course 1 and 2. However, reasonable disease control can often be achieved in these patients upon completion of the two-course regimen.
Alemtuzumab also slowed the annual rate of BVL in early relapsers over 6 years to rates almost as low as those of the overall CARE-MS population. [4] [5] [6] Given the link between brain atrophy and long-term disability, 25 the slowing effect of alemtuzumab on BVL should be expected to minimize future disability worsening even in patients who relapsed after the first course.
During the 4-year extension study, early relapsers were approximately 1.5 times more likely to receive a third alemtuzumab course and, on average, received it 5 months sooner, compared with early non-relapsers. Higher retreatment rates in this subgroup reflect the protocol requirement for disease activity as a condition of eligibility for receiving additional alemtuzumab courses in the extension. Nevertheless, 54% (CARE-MS I) and 40% (CARE-MS II) of early relapsers did not receive additional alemtuzumab after Course 2, and 90% and 86% did not receive another DMT, suggesting that disease activity was sufficiently controlled in many of these patients after completion of the two-course regimen.
Treatment sequencing has potential implications for disease activity after the first alemtuzumab course. A retrospective analysis of 50 patients transitioning from fingolimod to alemtuzumab showed a strong reduction in disease activity within 12 months after the switch. 26 However, in another series of patients treated sequentially with fingolimod and then alemtuzumab, nine were identified as experiencing disease activity within 12 months after alemtuzumab Course 1. 27 Even though animal studies showed some degree of lymphocyte depletion in lymph nodes after alemtuzumab administration, 8 the authors speculated that residual sequestration in lymph nodes after cessation of fingolimod treatment could protect lymphocytes from alemtuzumab-mediated depletion and contribute to persistence of disease activity. 27 Importantly, eight of those nine patients were relapse free after completing the two-course regimen. In the CARE-MS studies, no patients had a treatment history of fingolimod before enrollment. Nonetheless, an appropriate washout period may be advisable when transitioning to alemtuzumab from other agents with lymphopenic effects. 28 A limitation of this post hoc study is that the early relapsing and early non-relapsing subgroups were retrospectively defined and differed on multiple measures of MS disease severity at baseline, including relapse frequency before the first alemtuzumab course. The substantial difference in the size of the two subgroups (early relapsers, n = 161; early non-relapsers, n = 650) may further confound statistical comparisons. Thus, comparisons between these groups must be interpreted with caution. A second limitation is that this study was not designed to evaluate the effectiveness of switching to another therapy in comparison with receiving the second alemtuzumab course.
Conclusion
Alemtuzumab, administered in two annual courses, constitutes a unique treatment approach that does not require regular dosing to achieve and maintain efficacy. [4] [5] [6] 28 Some patients may relapse between the two initial alemtuzumab courses, but improved outcomes following Course 2 suggest that the two-course regimen, per the approved labeling, could maximize clinical and MRI benefits.
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